<b>Structural Determinants of Non-Covalent PPARγ Inverse Agonism and Their Therapeutic Implications</b>
<p dir="ltr">Peroxisome proliferator-activated receptor gamma (PPARγ) is a validated therapeutic target for type 2 diabetes (T2D), but current FDA-approved agonists are limited by adverse effects. SR10171, a non-covalent partial inverse agonist with modest binding potency, improves i...
Spremljeno u:
| Glavni autor: | |
|---|---|
| Daljnji autori: | |
| Izdano: |
2025
|
| Teme: | |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|